BUZZ-CervoMed jumps on dementia drug trial data

Reuters
07-28
BUZZ-<a href="https://laohu8.com/S/CRVO">CervoMed</a> jumps on dementia drug trial data

** Shares of drug developer CervoMed CRVO.O rise 58.7% to $14.25 premarket

** Co says its experimental drug, neflamapimod, significantly slowed disease progression in patients with dementia with Lewy bodies, the second most common form of dementia, based on 32-week extension data from its mid-stage trial

** The extension data come after a setback last December, when the drug failed to meet primary and secondary goals in the same trial, dragging its shares by 79%

** Patients who took neflamapimod showed a 54% lower risk of their disease getting worse compared to those who did not take the drug, co says

** Neflamapimod also reduced blood markers that indicate brain cell damage

** CRVO plans to meet with FDA in Q4 2025 to discuss late-stage trials

** As of last close, stock

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10